Anzeige
Meldung des Tages: Der Vorteil des Meeresbodens: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Nektar Therapeutics News

Aktie
WKN:  A419UB ISIN:  US6402683063 US-Symbol:  NKTR Branche:  Biotechnologie Land:  USA
71,50 €
+0,50 €
+0,70%
19:17:18 Uhr
Depot/Watchlist
Marktkapitalisierung *
7,03 Mrd. €
Streubesitz
27,94%
KGV
-5,04
Index-Zuordnung
-

Nektar Therapeutics News

30.01.26 - PR Newswire
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
22.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR PR Newswire
15.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR PR Newswire
08.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR PR Newswire
01.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR PR Newswire
16.12.25 - PR Newswire
REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata
REZOLVE-​AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-​of-Concept in Patients with Severe-​to-Very-Severe Alopecia Areata PR Newswire
15.12.25 - PR Newswire
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-​AA Phase 2b Study of Rezpegaldesleukin in Alopecia ...
05.12.25 - PR Newswire
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08.11.25 - PR Newswire
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
New Data from REZOLVE-​AD Study of Rezpegaldesleukin Presented in Late-​Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting PR Newswire
06.11.25 - PR Newswire
Nektar Therapeutics Reports Third Quarter 2025 Financial Results
Nektar Therapeutics Reports Third Quarter 2025 Financial Results PR Newswire
30.10.25 - PR Newswire
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London PR Newswire
28.10.25 - PR Newswire
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets PR Newswire
22.10.25 - PR Newswire
Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
Data from REZOLVE-​AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-​Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting PR Newswire
18.09.25 - PR Newswire
Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
Nektar Presents New Data from REZOLVE-​AD Phase 2b Study for Rezpegaldesleukin in Late-​Breaker Oral Presentation at EADV 2025 PR Newswire
09.09.25 - PR Newswire
Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025
Nektar Announces REZOLVE-​AD Phase 2b Results for Rezpegaldesleukin Selected for Late-​Breaker Oral Presentation at EADV 2025 PR Newswire
03.09.25 - PR Newswire
Nektar Therapeutics to Participate in Two Investor Conferences in September
Nektar Therapeutics to Participate in Two Investor Conferences in September PR Newswire
14.08.25 - PR Newswire
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment PR Newswire
07.08.25 - PR Newswire
Nektar Therapeutics Reports Second Quarter 2025 Financial Results
Nektar Therapeutics Reports Second Quarter 2025 Financial Results PR Newswire
31.07.25 - PR Newswire
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets PR Newswire
29.07.25 - PR Newswire
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-​to-Very Severe Alopecia Areata PR Newswire

Newssuche

Videos

newspaper
16.04.26 +3,58%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »